CholBiomeVH addresses vascular health and joins the three other cardiovascular ingredients in ProBiotix’s CholBiome line.
ProBiotix Health Plc (UK) is now offering a private-label probiotic formula called CholBiomeVH. Targeting the heart health market, CholBiomeVH leverages ProBiotix Health’s experience in probiotics. The formula joints three other existing formulas in the CholBiome cardiovascular probiotic line: CholBiome, CholBiomex3, and CholBiomeBP.
All of these formulas feature the ProBiotix LPLDL Lactobacillus plantarum probiotic ingredient. This patented probiotic strain has been shown to improve key cardiovascular biomarkers, including cholesterol (reducing LDL and increasing HDL) and blood pressure.
The company describes CholBiomeVH as “a vascular health formula that combines three specialized ingredients in a triple-layer tablet." It comprises LPLDL, thiamine, and Vitamin K2 Vital (from Kappa Bioscience) "to provide a multi-targeted mechanism to work against the buildup of lipid and calcium deposits in blood vessels.”
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.